Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives

Triple-negative breast cancer (TNBC) is characterized by the lack of clinically significant levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Owing to the aggressive nature and the emergence of resistance to chemotherapeutic drugs, pat...

Full description

Bibliographic Details
Main Authors: Huimei Yi, Ying Li, Yuan Tan, Shujun Fu, Faqing Tang, Xiyun Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
triple-negative breast cancer
immune checkpoint
PD1/PDL1
CTLA4
Immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.648139/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.648139/full

Similar Items